Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Replaced original description with the provided description, preserving markdown and escaping double quotes and newlines: "**Acetaminophen + isometheptene mucate + dichloralphenazone** is a combination pharmaceutical product formerly approved and widely used for the acute treatment of tension headaches, vascular headaches, and migraines. It consists of three active ingredients: - **Acetaminophen**: a non-salicylate analgesic and antipyretic that increases the pain threshold, providing general headache relief. - **Isometheptene mucate**: a sympathomimetic amine that causes vasoconstriction of dilated cranial and cerebral blood vessels, reducing vascular headache symptoms. - **Dichloralphenazone**: a sedative that diminishes the emotional response to pain, enhancing overall symptomatic relief. The product was frequently used for acute headache episodes, particularly migraines, but has been discontinued in the US due to regulatory concerns regarding the unapproved status of isometheptene mucate and dichloralphenazone, not for safety or efficacy issues. Some compounded versions may still be available in limited circumstances[1][2][3][4][5][6][7][8]."
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetaminophen + isometheptene mucate + dichloralphenazone.